Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
LLY$1,358.94-8.16(-0.60%)Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence7:18:02 PM ETGOOG$284.41+2.54(+0.90%)Google executive Donald Harrison resigns from SpaceX board6:48:40 PM ETORCL$115.93+0.85(+0.74%)Oracle Just Sold $10 Billion of Stock at $116 a Share. Is the Stock a Buy at That Price?6:41:02 PM ETBRK-A$855,999.77-1,487.77(-0.17%)A Berkshire Hathaway Electric Utility Wants a Historic Rate Hike in California6:33:00 PM ETAAPL$342.70-1.70(-0.49%)Dividend Champion, Contender, And Challenger Highlights: Week of November 86:30:37 PM ETAAPL$342.70-1.70(-0.49%)Apple's secret list of banned autocomplete phrases include ‘Dictator Trump,' ‘Sleepy Joe'6:25:27 PM ETWMT$125.42-2.18(-1.71%)His Job Is to Turn Walmart's Customer Data Into Profit6:25:00 PM ETSPGI$467.80-4.82(-1.02%)James Hardie Industries Set to Join S&P MidCap 4006:10:21 PM ETACCS$3.40-0.09(-2.58%)VapoLung Customer Reviews 2026: The Vapo Lung Spray Respiratory Wellness Appeal-What Are You Getting?6:05:00 PM ETORCL$115.93+0.85(+0.74%)A Retiree Who Bought 1,000 Oracle Shares at $39 Just Watched Microsoft Walk Away5:48:41 PM ETMU$692.90+35.44(+5.39%)Stock Market Today, Nov. 6: Micron Technology Jumps as Chip Stocks Rebound From Thursday's Rout5:36:15 PM ETRY$200.97-2.81(-1.38%)LIVE MARKETS-Stocks recover some of previous day's losses5:31:39 PM ETGOOG$284.41+2.54(+0.90%)SpaceX says Google exec Don Harrison has resigned from its board5:30:22 PM ETCVX$214.34+1.45(+0.68%)Compared to Estimates, Chevron (CVX) Q3 Earnings: A Look at Key Metrics5:30:02 PM ETAPO$116.01-1.27(-1.08%)UPDATE 3-Swiss dental startup vVardis eyes $4.4 billion valuation in US IPO5:23:16 PM ETWM$236.26-5.01(-2.08%)Waste management firm Avalon's Q3 profit rises5:16:54 PM ETCNQ$48.67-0.23(-0.47%)Canadian Natural Resources Q3 Earnings Call Highlights5:15:44 PM ETAMD$447.89+44.21(+10.95%)Stock Market Today, Nov. 6: AMD Surges 11% on Record Quarterly Revenue and Stronger Growth Outlook5:05:02 PM ETTSLA$359.65+16.33(+4.76%)Friday's Final Takeaways: TSLA Cybertruck Era Ending, Asian Bear Markets Emerge5:00:34 PM ETXOM$166.20+0.86(+0.52%)Exxon (XOM) Reports Q3 Earnings: What Key Metrics Have to Say5:00:02 PM ETPH$916.00+22.87(+2.56%)Parker Scheduled to Present at Robert W. Baird Global Industrial Conference on November 10 at 10:50 a.m. Central Time (11:50 a.m. Eastern Time)5:00:01 PM ETPH$916.00+22.87(+2.56%)Parker Scheduled to Present at Robert W. Baird Global Industrial Conference on November 10 at 10:50 a.m.5:00:00 PM ETACN$260.02-5.26(-1.98%)Accenture (ACN) Stock Sinks As Market Gains: What You Should Know4:50:01 PM ETMRVL$141.72+8.40(+6.30%)BUZZ-US stocks weekly: Revolt4:48:25 PM ET

ROIV · NASDAQ

Roivant Sciences Ltd.

$38.88 +2.25 (+6.14%)

Company overview

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutic areas, including solid tumors, sickle cell disease, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye disease, sarcoidosis, and Staphylococcus aureus bacteremia. The company was founded in 2014 and is based in London, United Kingdom.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$28.1B
Employees
908
Headquarters
London
Website
roivant.com
CEO
Matthew Gline
Listed
December 8, 2020
P/E
-86.40
Dividend yield
0.00%

Company financials

Revenue
$8.3M
Gross profit
$7M
Operating income
-$1.3B
EBITDA
-$1.3B
Net income
-$300M
EPS
-$0.45
Total assets
$5.7B
Total debt
$107M
Gross margin
84.44%
Net margin
-3,629.19%
Earnings yield
-1.16%

Revenue segmentation

By product (FY 2025)

Reported on May 20, 2026

By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

26.9230.9735.0139.0543.10
ROIV 1D NASDAQ O38.23H38.27L36.44C36.62-1.61 (-4.21%)Vol10.18M

News

LiveHeadlines show up as soon as they are ingested, with ticker, type, source, and time.

Pro

15-min delayYour Free plan is delayed 15 minutes. Pro opens the live desk.

Start 7-day free trial See live plans

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans

Since 2020This range is older than the last year on your plan. Pro opens articles since 2020.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
ROIVRoivant Sciences Ltd. Stock news Moderna pressed by US judges on billion-dollar COVID patent defense Reuters
ROIVRoivant Sciences Ltd. Press release Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift GlobeNewswire
ROIVRoivant Sciences Ltd. Press release Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 GlobeNewswire
ROIVRoivant Sciences Ltd. Press release Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) GlobeNewswire
ROIVRoivant Sciences Ltd. Press release Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 GlobeNewswire
ROIVRoivant Sciences Ltd. Stock news This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Benzinga
ROIVRoivant Sciences Ltd. Stock news Roivant’s Eric Venker sells 200,000 shares after option exercise (NASDAQ: ROIV) Defense World
ROIVRoivant Sciences Ltd. Stock news Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months Defense World
ROIVRoivant Sciences Ltd. Stock news Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months MarketBeat
ROIVRoivant Sciences Ltd. Press release Immunovant Announces Topline Results from Proof-of-Concept GlobeNewswire
ROIVRoivant Sciences Ltd. Press release Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus GlobeNewswire
ROIVRoivant Sciences Ltd. Stock news Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript Seeking Alpha
ROIVRoivant Sciences Ltd. Stock news This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Benzinga
ROIVRoivant Sciences Ltd. Stock news Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants Seeking Alpha
ROIVRoivant Sciences Ltd. Stock news Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Seeking Alpha
ROIVRoivant Sciences Ltd. Stock news Roivant Sciences Ltd. (ROIV) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Seeking Alpha
ROIVRoivant Sciences Ltd. Stock news Roivant Sciences Ltd. (ROIV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Seeking Alpha
ROIVRoivant Sciences Ltd. Stock news Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD Transcript Seeking Alpha
ROIVRoivant Sciences Ltd. Stock news Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings Benzinga
ROIVRoivant Sciences Ltd. Stock news Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate Benzinga
See more
FAQ

Questions about Roivant Sciences Ltd.

What does Roivant Sciences Ltd. do?
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutic areas, including solid tumors, sickle cell disease, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye disease, sarcoidosis, and Staphylococcus aureus bacteremia. The company was founded in 2014 and is based in London, United Kingdom.
What is ROIV's market cap?
Roivant Sciences Ltd. (ROIV) is a listed stock with a live quote. The latest market cap on this page is $28.1B.
Where is Roivant Sciences Ltd. headquartered?
Roivant Sciences Ltd. is headquartered in London.
How do I get ROIV news from the API?
Call GET /v1/news?tickers=ROIV. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does ROIV news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ROIV, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the ROIV price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs